EDAP TMS S.A. (EDAP) EPS Estimated At $-0.03

November 10, 2018 - By Peter Kolinski

EDAP TMS S.A. (NASDAQ:EDAP) Logo

Analysts expect EDAP TMS S.A. (NASDAQ:EDAP) to report $-0.03 EPS on November, 21.They anticipate $0.01 EPS change or 50.00 % from last quarter’s $-0.02 EPS. After having $-0.03 EPS previously, EDAP TMS S.A.’s analysts see 0.00 % EPS growth. The stock decreased 3.60% or $0.09 during the last trading session, reaching $2.41. About 56,478 shares traded or 34.24% up from the average. EDAP TMS S.A. (NASDAQ:EDAP) has declined 10.78% since November 11, 2017 and is downtrending. It has underperformed by 26.40% the S&P500.

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company has market cap of $69.89 million. The firm operates in two divisions: High Intensity Focused Ultrasound , and Urology Devices and Services (UDS). It currently has negative earnings. The HIFU division develops, makes, and markets devices for the minimally invasive destruction of various types of localized tumors using HIFU technology.

More recent EDAP TMS S.A. (NASDAQ:EDAP) news were published by: Nasdaq.com which released: “EDAP TMS SA : EDAP Announces Expiration of Tranche of Outstanding Warrants” on October 15, 2018. Also Nasdaq.com published the news titled: “EDAP TMS SA : EDAP TMS SA to Announce Third Quarter 2018 Financial Results on Wednesday, November 14” on October 19, 2018. Globenewswire.com‘s news article titled: “EDAP TMS SA : Urologic Oncologists from Top US Teaching Hospitals Gather in Montreal to Learn Advanced Prostate …” with publication date: October 25, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>